Colinz Laboratories Open Offer: 2026 Dates, Price Guide

Why Colinz Laboratories is in focus

Colinz Laboratories Limited has received a public announcement for a mandatory open offer after a change-of-control transaction was agreed with the existing promoter. The offer is being made under the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The Committee of Independent Directors (IDC) of Colinz Laboratories has recommended that eligible shareholders accept the open offer. The open offer provides a cash exit route to public shareholders at a stated price of ₹54 per equity share. The proposal comes alongside a larger stake acquisition agreed through a Share Purchase Agreement (SPA). For investors tracking micro and small-cap control transactions, the schedule, pricing, and tendering mechanics are the key items to monitor.

IDC recommendation and what it means

The IDC has recommended that eligible shareholders accept the open offer initiated by Annjana Dugar, Likhitta Dugar, Antariksh Dugar, and Padam Dugar (collectively referred to as the acquirers). An IDC recommendation typically signals that independent directors have reviewed the offer terms and process disclosures available to them. It does not change the tendering mechanics, but it can influence how minority shareholders interpret governance and fairness considerations. In this case, the recommendation is tied directly to the announced mandatory open offer. Shareholders still retain the choice to tender or not, depending on their view of the offer price and the company’s outlook. The recommendation also places emphasis on the official timeline and eligibility dates.

Who the acquirers are

The acquirers named in the disclosures are Annjana Dugar, Likhitta Dugar, and Antariksh Dugar. Padam Dugar is identified as the Person Acting in Concert (PAC) in the transaction structure. The open offer is being made to public shareholders following the agreed acquisition from the existing promoter. The stated intent is to acquire up to 6,54,966 fully paid-up equity shares. These shares represent 26% of Colinz Laboratories’ voting share capital on a fully diluted basis. The transaction is positioned as part of a change in management control.

What triggered the mandatory open offer

The open offer has been triggered following an SPA dated June 18, 2026. Under the SPA, the acquirers agreed to purchase 8,70,500 shares representing a 34.56% stake from existing promoter Vijaya Mani. The disclosed price for the SPA transaction is ₹50 per share. Another disclosure also references INR 43.5 million for this acquisition, which corresponds to ₹4.35 crore. This stake purchase, combined with takeover code thresholds and change-of-control considerations, necessitated a mandatory open offer to public shareholders for an additional 26%. Separately, there is also a data point stating that Padam Dugar acquired a 15.01% stake in Colinz Laboratories on May 26, 2026.

Open offer terms: size, price, and cash payout

The open offer is for up to 6,54,966 fully paid-up equity shares of face value ₹10 each. This represents 26% of the company’s voting share capital on a fully diluted basis. The offer price is set at ₹54 per equity share. The maximum cash consideration for the open offer is stated as ₹3,53,68,164, which is about ₹3.5368 crore. The consideration is payable in cash. Public shareholders holding shares in dematerialised as well as physical form are eligible to participate.

Key dates: tendering window and payment schedule (two versions)

Two schedules of activities are cited across the provided disclosures. One revised schedule states that the tendering period will commence on Thursday, August 06, 2026, and conclude on Wednesday, August 19, 2026. In the same schedule set, the identified date for determining eligible shareholders is Thursday, July 23, 2026. That revised schedule also states that payment of consideration or return of equity shares is scheduled to be completed by Thursday, September 03, 2026.

Another set of disclosures states that the tendering period is scheduled to open on August 11, 2026, and close on August 24, 2026. Those disclosures also state the last date for payment of consideration to shareholders as September 8, 2026. Investors typically rely on the final schedule in the offer documents and stock exchange filings, and should align actions to the dates applicable to their broker’s tendering workflow. Where more than one timeline appears in circulation, shareholders generally track the latest published schedule and instructions on the exchange platform.

Funding arrangements: escrow deposit disclosed

To fund the open offer, the acquirers have opened an escrow cash account with ICICI Bank. The disclosed escrow deposit is ₹89 lakh, which is ₹0.89 crore. Escrow funding is a standard safeguard in open offers, intended to demonstrate the acquirers’ ability to meet payment obligations for shares tendered and accepted. The open offer consideration is payable in cash, so the funding pathway matters for execution certainty. The escrow detail is one of the concrete financial disclosures around the offer process.

How shareholders can participate

Tendering is to be done through the BSE acquisition window, as per the disclosed process. Public shareholders holding shares in both dematerialized and physical forms are eligible to participate. In practice, shareholders tender through their broker using the acquisition window mechanism during the tendering period. Eligibility is determined based on the identified date disclosed as July 23, 2026 in one of the schedules. Shareholders who do not tender keep their holdings, while those who tender participate in the open offer acceptance process as per regulations and final offer terms. Any unaccepted shares are returned, and accepted shares receive cash consideration within the stated payment timeline.

Market context: offer price versus reported market price

One disclosure states Colinz Laboratories’ share price was ₹71.96 as of 24 Jun, 2026. Against that reference, the open offer price of ₹54 per share is lower than the stated market price on that date. The SPA purchase price disclosed for the promoter stake is ₹50 per share, while the open offer price to public shareholders is ₹54 per share. These are the two key pricing markers in the transaction: the negotiated control-block price and the regulated open offer price. For shareholders deciding whether to tender, the practical comparison is between the open offer price and prevailing market prices during the tender window, alongside liquidity considerations.

Summary table: key disclosed terms

Why the transaction matters for control and public shareholders

The disclosures indicate that the company is set for a change of control following the June 18, 2026 SPA. One statement also notes that upon completion, the acquirers’ shareholding will increase to 37.01%, alongside the mandatory open offer for 26%. A change-of-control deal typically shifts board oversight, strategic priorities, and promoter influence, even when the public float remains. For public shareholders, the open offer creates a defined cash exit option at a fixed price, subject to acceptance. The IDC’s recommendation adds a governance layer to the decision framework, though it does not alter price or eligibility. The key near-term events are the tendering period, the exchange-based tender process, and the scheduled payout date.

Conclusion

Colinz Laboratories’ mandatory open offer at ₹54 per share for 6,54,966 shares (26%) follows a June 18, 2026 SPA in which the Dugar family acquirers agreed to buy a 34.56% stake from promoter Vijaya Mani at ₹50 per share. The IDC has recommended that eligible shareholders accept the offer. Shareholders should track the tendering window and payment dates as disclosed in the final schedule applicable to the offer, noting that two different date sets appear in the available information. Participation is through the BSE acquisition window, and the consideration is payable in cash. The next concrete milestones are the tender period opening and the subsequent payment or return of shares by the stated settlement date.